Fujifilm expands fill/finish services for gene therapies in Texas

By Flora Southey contact

- Last updated on GMT

(Image: Getty/gustavofrazao)
(Image: Getty/gustavofrazao)
Fujifilm Diosynth Biotechnologies has added fill/finish capabilities for late-phase and commercial supply of gene therapies and viral vaccines.

The Japanese contract development and manufacturing organisation (CDMO) has invested in Vanrx Pharmasystems’ SA25 Aseptic Filling Workcell technology to offer “end to end” ​manufacturing services at its flexible manufacturing facility (FBF) in Texas, US.

The 80,000 square-foot plant in College Station – acquired from Kalon Therpaeutics in 2014​ – opened in January this year​.

The fill/finish investment will enable clients to “swiftly”​ advance therapies from bulk drug substance into commercial production, said COO Gerry Farrell in a statement.

“We recognised that having Fill Finish capabilities that extend beyond the current clinical stage is essential to support the rapid delivery of clinical candidates to patients," ​he added.

The announcement is the latest in a line of bioprocessing investments for Fujifilm Corporation, which acquired Diosynth Biotechnologies from Merck & Co. in 2011.

In April last year, the firm said​ it would spend ¥3bn ($27.4m) on mammalian cell culture bioreactors at its Texas-based FBF. The company also announced plans to build a ¥1bn process development facility at its facility in Billingham, UK.

Additionally, in March​ this year, Fujifilm paid $800m (€650m) for cell culture media firm Irvine Scientific.

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us


View more